Changes to This Summary (04/27/2012)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Prostate Cancer Susceptibility Loci ¹

Added text ² to state that despite demonstrating a modest increase in prostate cancer risk among men with one of the Ashkenazi Jewish founder mutations and a more substantial increase in risk among BRCA2 carriers, the lack of a proven prostate cancer screening strategy prevents basing management decisions on this information.

Added text ³ about a study that reported a median survival of 4 years in 183 men with prostate cancer with a BRCA2 mutation and a median survival of 8 years in 119 men with a BRCA1 mutation. Also added text about a study that reported a median overall survival of 4.8 years in BRCA2 mutation–positive prostate cancer cases and 8.5 years in noncarriers with prostate cancer (cited Edwards et al. as reference 136).

Added text ⁴ about a study that assessed the contribution of prostate cancer as a feature of Lynch Syndrome in which the authors concluded that microsatellite instability is rare in hereditary prostate cancer and that prostate cancer is uncommon in Lynch Syndrome (cited Bauer et al. as reference 144).

The Genome-Wide Association Studies ⁵ subsection was extensively revised.

Added text ⁶ about a study that examined the association between prostate cancer–specific mortality (PCSM) and 846 single nucleotide polymorphisms (SNPs) in a population-based prostate cancer cohort and found 22 SNPs to be significantly associated with PCSM (cited Lin et al. as reference 225).